Literature DB >> 24285678

Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.

Yoshitsugu Iwakura1, Ryo Morimoto, Masataka Kudo, Yoshikiyo Ono, Kei Takase, Kazumasa Seiji, Yoichi Arai, Yasuhiro Nakamura, Hironobu Sasano, Sadayoshi Ito, Fumitoshi Satoh.   

Abstract

CONTEXT: In primary aldosteronism (PA), glomerular hyperfiltration due to excessive aldosterone is considered to underestimate actual renal damage.
OBJECTIVE: Our objectives were to determine the prevalence of chronic kidney disease (CKD) in PA and identify the predictors of decreasing estimated glomerular filtration rate (eGFR) after treatment. DESIGN AND
SETTING: This was a 12-month prospective study of patients with PA treated at Tohoku University Hospital. PATIENTS AND
INTERVENTIONS: All patients were treated according to the results of adrenal venous sampling; 102 patients with aldosterone-producing adenoma underwent adrenalectomy, and 111 with bilateral hyperaldosteronism were treated with mineralocorticoid receptor antagonists. MAIN OUTCOME MEASURES: Electrolytes, blood pressure, and indicators of renal function were determined at 1 and 12 months after intervention.
RESULTS: Blood pressure, urinary albumin excretion (UAE), and eGFR, which significantly decreased at 1 month after treatment of PA, did not further decrease at 12 months. Prevalence of CKD, which was 15.7% in aldosterone-producing adenoma and 8.1% in bilateral hyperaldosteronism at the first visit, increased to 37.1% and 28.3%, respectively, at the end of study (P < .0001). Multivariate regression analysis revealed that higher UAE and lower serum potassium levels were found to be independent predictors of decreasing eGFR after intervention.
CONCLUSIONS: This large cohort study shows that the prevalence of CKD in PA was increased after treatment and that higher UAE and lower serum potassium levels at the first visit were predictors of decreasing eGFR after treatment of PA. To prevent a large decrease of eGFR after intervention, PA patients should be diagnosed before evolution to severe albuminuria and hypokalemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24285678     DOI: 10.1210/jc.2013-2180

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism.

Authors:  Takanobu Utsumi; Naoto Kamiya; Mayuko Kaga; Takumi Endo; Masashi Yano; Shuichi Kamijima; Koji Kawamura; Takashi Imamoto; Tomohiko Ichikawa; Hiroyoshi Suzuki
Journal:  World J Urol       Date:  2017-04-11       Impact factor: 4.226

Review 2.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

3.  Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function.

Authors:  Il Young Kim; In Seong Park; Min Jeong Kim; Miyeun Han; Harin Rhee; Eun Young Seong; Dong Won Lee; Soo Bong Lee; Ihm Soo Kwak; Sang Heon Song; Hyun Chul Chung
Journal:  Int Urol Nephrol       Date:  2018-05-19       Impact factor: 2.370

4.  Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.

Authors:  Aya T Nanba; Taweesak Wannachalee; James J Shields; James B Byrd; William E Rainey; Richard J Auchus; Adina F Turcu
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

5.  Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas.

Authors:  Yoshikiyo Ono; Yasuhiro Nakamura; Takashi Maekawa; Saulo J A Felizola; Ryo Morimoto; Yoshitsugu Iwakura; Masataka Kudo; Kazumasa Seiji; Kei Takase; Yoichi Arai; Celso E Gomez-Sanchez; Sadayoshi Ito; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2014-05-19       Impact factor: 10.190

6.  Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report.

Authors:  Hiroyuki Hirai; Makoto Kanno; Tsuyoshi Watanabe; Hiroaki Satoh
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

7.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

8.  Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.

Authors:  Ryo Morimoto; Yoshikiyo Ono; Yuta Tezuka; Masataka Kudo; Sachiko Yamamoto; Toshiaki Arai; Celso E Gomez-Sanchez; Hironobu Sasano; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

Review 9.  Primary Aldosteronism: a Continuum from Normotension to Hypertension.

Authors:  Taweesak Wannachalee; Adina F Turcu
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

10.  Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.

Authors:  Shigehiro Karashima; Takashi Yoneda; Mitsuhiro Kometani; Masashi Ohe; Shunsuke Mori; Toshitaka Sawamura; Kenji Furukawa; Takashi Seta; Masakazu Yamagishi; Yoshiyu Takeda
Journal:  Hypertens Res       Date:  2015-11-26       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.